|Articles|August 24, 2015
D. Ross Camidge on the Development of a New Lung Cancer Drug
Author(s)D. Ross Camidge
D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).
Advertisement
D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of
Camidge presented results from a study of brigatinib during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology professionals in Chicago.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Advisory Committee Backs RP1 for Advanced Melanoma
2
Living With Lung Cancer, Not Dying From It: One Survivor's Story of Hope
3
Same-Day Discharge and Single-Incision Surgery Are Changing Rectal Cancer Care
4
Oncology Researcher Brings Science, Compassion and Personal Loss to Cancer Care
5